The Journal of Dermatology

<jats:title>ABSTRACT</jats:title><jats:p>High‐dose radiotherapy is the standard treatment for cutaneous angiosarcoma (CAS); however, adverse events and organ toxicity remain major challenges. Intensity‐modulated radiation therapy using tomotherapy allows the precise targeting of complex lesions. We retrospectively reviewed 12 patients with CAS who were treated with tomotherapy and paclitaxel between January 2017 and April 2024. Clinical outcomes, including progression‐free survival, overall survival, and adverse events, were analyzed and compared with those of the historical controls. The median progression‐free survival was 10.5 months (95% confidence interval: 7.7–not reached). The 2‐year overall survival and progression‐free survival rates were 70.0% and 41.7%, respectively. Grade ≥ 3 adverse events occurred in a limited number of patients, including radiation‐induced dermatitis (<jats:italic>n</jats:italic> = 1), neutropenia (<jats:italic>n</jats:italic> = 2), peripheral neuropathy (<jats:italic>n</jats:italic> = 1), and corneal toxicity (<jats:italic>n</jats:italic> = 1). Nevertheless, the treatment regimen was generally well tolerated and achieved favorable survival outcomes, representing a safe and effective treatment option.</jats:p>

publication_history

received

accepted

published

Cutaneous Angiosarcoma: A Review of Current Evidence for Treatment With Checkpoint Inhibitors

Frontiers in Medicine

Cutaneous Angiosarcoma: The Possibility of New Treatment Options Especially for Patients With Large Primary Tumor

Frontiers in Oncology

The Effectiveness of Different Treatment Modalities of Cutaneous Angiosarcoma: Results From Meta‐Analysis and Observational Data From SEER Database

Efficacy of a Combination of Paclitaxel and Radiation Therapy Against Cutaneous Angiosarcoma: A Single‐Institution Retrospective Study of 21 Cases

Journal of Dermatology

High‐Dose Planned Adaptive Helical Tomotherapy for Cutaneous Angiosarcoma of the Scalp

Strahlentherapie und Onkologie

A Successful Approach for Angiosarcoma of the Scalp Using Helical Tomotherapy and Customized Surface Mold Brachytherapy: A Case Report

Medicine (Baltimore)

Definitive Radiotherapy Using Electron Beam and Intensity‐Modulated Radiotherapy for Unresectable Angiosarcoma of the Scalp

Anticancer Research

Chemoradiotherapy With Taxane Is Superior to Conventional Surgery and Radiotherapy in the Management of Cutaneous Angiosarcoma: A Multicentre, Retrospective Study

British Journal of Dermatology

Clinical Outcomes of Scalp or Face Angiosarcoma Treatment With Intensity‐Modulated Radiotherapy: A Multicenter Study

Journal of Radiation Research

High-dose radiotherapy is the standard treatment for cutaneous angiosarcoma (CAS); however, adverse events and organ toxicity remain major challenges. Intensity-modulated radiation therapy using tomotherapy allows the precise targeting of complex lesions. We retrospectively reviewed 12 patients with CAS who were treated with tomotherapy and paclitaxel between January 2017 and April 2024. Clinical outcomes, including progression-free survival, overall survival, and adverse events, were analyzed and compared with those of the historical controls. The median progression-free survival was 10.5 months (95% confidence interval: 7.7-not reached). The 2-year overall survival and progression-free survival rates were 70.0% and 41.7%, respectively. Grade ≥ 3 adverse events occurred in a limited number of patients, including radiation-induced dermatitis (n = 1), neutropenia (n = 2), peripheral neuropathy (n = 1), and corneal toxicity (n = 1). Nevertheless, the treatment regimen was generally well tolerated and achieved favorable survival outcomes, representing a safe and effective treatment option.

Efficacy and Safety of Helical Tomotherapy Combined With Paclitaxel in Cutaneous Angiosarcoma.

Efficacy and Safety of Helical Tomotherapy Combined With Paclitaxel in Cutaneous Angiosarcoma

Papers